Instituto de Neumonologia y Dermatologia | Buenos Aires, Argentina

Research site

(Unclaimed)

Location

Arenales 2557 1A, Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

Site insights

Top conditions

Top treatments

Rocatinlimab

Ustekinumab

Lebrikizumab

Deucravacitinib

JNJ-77242113

JNJ-95475939

TAK-279

Ruxolitinib

Upadacitinib

Dupilumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 14 total trials

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib

Drug: Dupilumab

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting

Plaque Psoriasis

Drug: Ustekinumab

Drug: Matching Placebo to Ustekinumab

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

Enrolling

NonSegmental Vitiligo

Drug: Vehicle Cream

Drug: Ruxolitinib Cream

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Active, not recruiting

Prurigo Nodularis

Drug: Povorcitinib

Drug: Placebo

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (ADsolve)

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic d...

Active, not recruiting

Atopic Dermatitis

Drug: Lebrikizumab